Cosmax BTI, Inc. Overview
Cosmax BTI is the apex holding company of the Cosmax Group, the Korean-founded enterprise widely described as the world's largest cosmetics original design manufacturer (ODM). Its economic value rests on three layers. First, an equity-method stake of roughly 27% in Cosmax, Inc., the group's listed cosmetics ODM, which reported record FY2025 revenue of KRW 2,398.8 bn and operating profit of KRW 195.8 bn. Second, controlling stakes in a health-functional-food (HFF) ODM platform — KOSDAQ-listed Cosmax NBT (43.53%) and unlisted Cosmax Bio (68.37%) — plus a small pharmaceutical subsidiary, Cosmax Pharma (79.64%). Third, its own "separate" operations: global raw-material purchasing and export agency for group companies, shared-services fees, and dividend income. Consolidated FY2025 revenue was KRW 645.2 bn with operating profit of KRW 27.0 bn. The stock trades at a deep discount to the market value of its listed holdings, and family succession was formalised in May 2026.
What the company does
Cosmax BTI performs two functions simultaneously:
-
Pure holding/control function. It sets group vision and strategy, allocates capital, oversees human-resources and financing plans, and holds controlling or significant stakes in operating companies. The company's own description (group website) characterises BTI as the body that sets strategic goals and develops HR and financing plans for the whole Cosmax Group, while securing growth engines in health and functional foods, bio-capsules and new businesses beyond the cosmetics core.
-
Operating ("business holding") function. The parent entity itself books revenue from (a) sales of goods and merchandise — principally global raw-material procurement and export agency services for subsidiaries and the Cosmax, Inc. associate; (b) shared-services-center (SSC) fees and service revenue; and (c) dividend income from affiliates. Per a valuation-platform summary of the FY2025 annual report, BTI had 14 consolidated subsidiaries as of June 2025 and performs global raw-material purchasing and export agency for subsidiaries.
Reporting segments (as presented in company IR materials)
| Segment | Entity | Ownership by BTI | Accounting | Business |
|---|---|---|---|---|
| Health functional food (NBT) | Cosmax NBT, Inc. (KOSDAQ: 222040) | 43.53% direct (43.93% incl. related parties), FY2025 annual report | Consolidated | HFF ODM/OBM with Korea–Australia–China–US value chain |
| Health functional food (BIO) | Cosmax Bio, Inc. (unlisted) | 68.37% (FY2025 annual report) | Consolidated | HFF ODM — tablets, softgels, liquids, jellies, powders |
| Pharma | Cosmax Pharma, Inc. (unlisted) | 79.64% (FY2025 annual report) | Consolidated | Pharmaceutical intermediates and finished drugs (CMO-type) |
| Holding (BTI separate) | Cosmax BTI parent | — | Parent | Raw-material sourcing/export agency, SSC fees, dividends |
| Cosmetics ODM (associate) | Cosmax, Inc. (KOSPI: 192820) | 27.23% direct; 27.51% incl. related parties (FY2025 annual report) | Equity method | World's largest cosmetics ODM |
Revenue model
Product (ODM/OEM manufacturing): the overwhelming majority of consolidated revenue — contract development and manufacturing of HFF and pharmaceuticals for brand owners (NBT, Bio, Pharma).
Trading/merchandise: BTI-separate procurement and resale of raw materials/merchandise to affiliates.
Services/fees: SSC and management-service fees.
Investment income: dividends (booked as revenue in BTI-separate; e.g., KRW 10.1 bn of FY2025 dividends recognised in Q1 2026) and equity-method income from Cosmax, Inc. (non-operating, below operating profit).
Subscription/licensing: not material / not disclosed.
Revenue mix by business (Q2 2026, per Butler/DART summary): health functional foods 64%, other (holding/trading) 32%, pharma 4%.
Value-chain position, customers and end-markets
The group sits in the B2B "invisible" middle of the beauty and wellness value chain — between ingredient suppliers and consumer brands. Customers are brand owners: global multinationals (Fortune's 2026 profile cites Shiseido, Yves Saint Laurent and Lancôme among Cosmax's roughly 4,500–5,000 customers), Korean "indie" K-beauty brands, Chinese domestic brands (e.g., Yatsen via JV), and, in HFF, network-marketing (MLM) companies, large retailers, home shopping, online channels, and pharma companies.
End-markets: skincare, color cosmetics, suncare, hair/body (via Cosmax, Inc.); dietary supplements/HFF (vitamins, probiotics, collagen, individually-recognised functional ingredients); and generic/OTC pharmaceutical products (Cosmax Pharma).
Independent characterisation
Economically, Cosmax BTI is best understood as a leveraged, owner-controlled holding vehicle whose net asset value is dominated by its Cosmax, Inc. stake, wrapped around a sub-scale and historically loss-making HFF manufacturing platform. Consolidated earnings understate BTI's look-through earnings power because Cosmax, Inc.'s profits arrive only as equity-method income and dividends. The investment case therefore hinges on (i) Cosmax, Inc.'s K-beauty-driven growth, (ii) whether the HFF turnaround visible in H1 2026 is durable, and (iii) whether governance and capital-allocation changes narrow the holding-company discount.
Strategy
Stated strategic themes
Holding-company role: set group vision/strategy; build HR and financing plans; secure growth engines in HFF, bio-capsules and new businesses beyond cosmetics.
Two-track growth (beauty + HFF): the group's long-standing "two-track" strategy; the HFF leg has underperformed (group HFF revenue ~KRW 460 bn in 2021 vs ~KRW 450 bn in 2025, per BizWatch).
Group revenue ambition: KRW 3 trillion group revenue target (recruitment-platform summary of company materials).
Customer diversification: reduce reliance on large clients; attract indie brands via lower minimum order quantities and smart-factory, high-mix/low-volume production.
Global production efficiency: Ohio exit, US integration, California sales expansion; NBT shift to sales-led US model.
Shareholder returns: dividend policy disclosure since 2023 to improve predictability; FY2025 payout 25.5%.
Initiatives in the last 24 months
| Initiative | Date | Description / target |
|---|---|---|
| Professional co-CEO model | Mar 2025 – Sep 2026 | Huh Min-ho tasked with holding-company system, mid/long-term strategy, management infrastructure, B2C/new business — ended with resignation |
| NBT US restructuring | 2025–2026 | Production ended; plant sold in two stages; proceeds earmarked for debt repayment |
| Cosmax Bio Jellix | Nov 2024 onward | Jelly-format capacity for domestic and export demand |
| K-health export support | 2025–2026 | NBT/Bio supporting Korean brands' exports; NBT USD 70 m and Bio USD 5 m export towers (Dec 2025) |
| Keminova acquisition (associate level) | Feb–Apr 2026 | First European base; post-merger integration, joint R&D, planned "Keminova Academy" |
| L'Oréal MOU (associate level) | Sep 2026 | Joint K-beauty-inspired global product development, ingredients, sensory formats |
| Value-up plan (Cosmax, Inc.) | Nov 2025 | Corporate value-enhancement plan; dividend predictability; governance improvement; annual ESG reports |
| High-dividend company status | Mar 2026 | Both BTI and Cosmax, Inc. qualified, enabling separate taxation of dividends for shareholders |
| Custom-cosmetics platform 3WAAU | Ongoing | One-to-one personalised production, B2C pilot |
| GrowX | 2026 (reported) | Marketing-consulting subsidiary for cosmetics/HFF |
Management targets / guidance
Cosmax BTI: no formal consolidated numeric guidance identified. Q4 2025 commentary: continued domestic HFF growth and export support with client-portfolio diversification; pharma to diversify customers and launch new products.
Cosmax, Inc. (associate) 2025 guidance (given Feb 2025): Korea revenue +20%, sun care +50%+, Korea OPM 10%; China East +10%; Indonesia +25%; Thailand +50%; US +10%+ and H2 breakeven. Outcome: Korea grew 12.4%; US breakeven slipped to Q2 2026.
Cosmax, Inc. Q2 2026 guidance (given May 2026): Korea mid-teens growth, China ~20%, US 30%+, Indonesia ~20%. Outcome: Korea +23%, China +33%, US +79%, Indonesia +38% — beat.
Cosmax Bio: 2021 target of KRW 500 bn revenue by 2026 — effectively abandoned (FY2025: KRW 168.2 bn).
Products & Services
Cosmax BTI does not sell branded consumer products at scale; its "products" are manufacturing and development capabilities offered to brand owners. Catalog by business:
Cosmax NBT (HFF ODM/OBM)
| Offering | Description / capability | Target customer | Notes |
|---|---|---|---|
| Custom HFF formulation & manufacturing | Multi-format supplements (tablets, capsules, powders etc.) across Korea, Australia, China; US now sales-led | MLM firms, retailers, global brands, China-bound brands | Overseas share >70% of revenue (2025) |
| Individually-recognised functional ingredients | 9 MFDS-approved proprietary ingredients incl. wheat-germ-oil extract | Brands seeking differentiated claims | Per FY2025 annual-report summary |
| Women's vaginal-health probiotic "Respecta" | Proprietary individually-recognised probiotic ingredient | Women's-health brands | Quarterly sales ~KRW 6 bn in Q1 2021 (IBK) |
| Australia premium export production | Plant oriented to premium products for China-bound clients | Global/China brands | Plant completed 2017 |
| Big-data prescription automation; micro-size formats | Digital-innovation and ultra-small dosage-form development | All | Recognised in 2025 ministerial commendation |
| US sales operation | Production ceased 2025; Korea plant supplies US clients | US brands | Plant sales: USD 14.25 m (first), second planned 2026 |
Cosmax Bio (HFF ODM)
| Offering | Description | Notes |
|---|---|---|
| Tablets, softgels, liquids, powders | Broad dosage-form capability | Korea and Shanghai |
| Jellies — "Jellix" line | Dedicated jelly production line built Nov 2024; first stick-type jelly format in Korea | Growth product |
| Individually-recognised ingredients | 5 MFDS approvals incl. perilla (차즈기) extract | Per FY2025 annual-report summary |
| Export programs | Halal and Australian TGA certifications; China >50% of exports; US, Vietnam, Indonesia, Kazakhstan | USD 5 m export tower (Dec 2025) |
Cosmax Pharma
Pharmaceutical intermediates and finished-drug manufacturing; product-level detail, pricing and flagship SKUs are not publicly disclosed in the sources reviewed.
Cosmax BTI (parent) services
| Offering | Description |
|---|---|
| Global raw-material purchasing | Group-level sourcing of cosmetic and HFF raw materials, resold to affiliates |
| Export agency | Export-agent services for subsidiaries |
| Shared services (SSC) | Fees for finance, HR and other group services |
| New-business incubation | Custom-cosmetics platform "3WAAU" (쓰리와우) for one-to-one personalised production (B2C pilot); marketing consulting (GrowX, reported 2026) |
Cosmax, Inc. (equity-method associate) — key capabilities
| Category | Detail |
|---|---|
| Skincare | Creams, serums, essences, sun care (sun care grew >50% in 2025 and reached ~10% of Korea sales in Q2 2025), gel masks |
| Color cosmetics | Cushions, foundations, blushers, lip, eye — Shanghai strength |
| Hair/body, fragrance, baby care, herbal cosmetics, cosmeceuticals | Full-category ODM |
| Scale | Korea capacity ~780 m units (end-2024) expanding to ~1 bn units (end-2025) |
| Product-mix trend | Korea skincare:color mix moved from 53:47 (Q1 2025) to 64:36 (Q1 2026) |
| Representative client brands (analyst-cited) | Medicube, Anua, Equalberry, Dr. Althea, Numbuzin, Dr. Rejuall (SK Securities, April 2026) |
| Pricing model | Per-unit ODM contract pricing; specific pricing not publicly disclosed |
Financial Narrative
Consolidated income statement
Sources: Revenue, operating income and FY2021–FY2024 net income from DART-based aggregator (Butler, FnGuide); FY2024–FY2025 gross profit and FY2025 net income (KRW 20.9 bn) from company Q4 2025 results summary (Quartr, March 2026). FY2021–FY2023 gross profit derived from published gross margins (16.0%, 14.3%, 17.5%). KRW 20.9 bn in company materials.
Revenue CAGR FY2021–FY2025: ≈2.9% p.a. (derived).
Attributable profit note (derived): FY2025 dividend of KRW 7.5 bn at a stated 25.5% payout implies consolidated profit attributable to owners of ≈KRW 29.4 bn, consistent with FnGuide FY2025 EPS of KRW 3,041. Attributable profit exceeds total net income because loss-making NBT (56% minority-owned) pushes losses onto non-controlling interests.
Quarterly trajectory: notes and sources
Sources: Cosmax BTI 1Q 2026 IR deck (quarterly chart, Q1'24–Q1'26); Q2 2026 derived from H1 2026 consolidated revenue KRW 444.1 bn and operating income KRW 32.6 bn (Seoul Times News, Oct 2026) minus Q1 2026.
H1 2026 vs H1 2025: notes and sources
Source: Seoul Times News (Oct 2026), DART-based. H1 2026 net income is inflated by the NBT tax refund (KRW 25.7 bn at NBT level) and higher equity-method income from Cosmax, Inc. (Q1 2026 equity-method income KRW 11.0 bn vs KRW 0.8 bn in Q1 2025).
Balance sheet
Sources: FY2024 — DART-based (Digital Today); FY2025 and Q1 2026 — Cosmax BTI 1Q 2026 IR deck. Discrepancy: a Q4 2025 summary (Quartr) reports FY2025 total assets of KRW 1,009.4 bn and equity of KRW 298.1 bn (vs. KRW 1,006.3 bn / 295.7 bn in the later IR deck — likely audit adjustments).
Cash & equivalents, total debt (short/long split), net debt, goodwill & intangibles: not publicly disclosed in the sources reviewed (the DART annual report would contain these; it was not directly accessible). Working capital (derived): FY2025 −KRW 278.2 bn; Q1 2026 −KRW 250.8 bn.
Cash flow
Operating cash flow, capex, free cash flow and buybacks for FY2021–FY2025: not publicly disclosed in sources reviewed. Dividends paid: FY2025 declared KRW 7.5 bn (paid 2026). No share buybacks identified; treasury shares (49,082) date from 2020.
Per-share data
Sources: FY2023 DPS KRW 350 (ETFshopping); FY2025 DPS KRW 780, +73.3% (Herald, CEO Score Daily, March 2026); FY2024 derived from the 73.3% increase. ETFshopping reports four consecutive annual dividend increases and a 5-year DPS CAGR of 25.6%. EPS: FY2025 KRW 3,041 (FnGuide, consolidated); TTM EPS KRW 6,641 (Judal, Oct 2026). Diluted EPS: not disclosed.
Commentary on trends, inflections and drivers
FY2021–FY2023: stagnation. Revenue rose only modestly from KRW 576.0 bn to KRW 628.6 bn as Korea's HFF market plateaued (KRW 6.15 tn in 2022 and 2023), NBT's US and Australian plants generated persistent losses (NBT US lost KRW 33.8 bn in 2022), and pharma remained in deficit. FY2022 was the trough: operating margin 0.6% and a net loss of KRW 20.2 bn.
FY2024: contraction. Revenue fell 4.9% to KRW 597.6 bn as domestic HFF demand softened (market −3.1% to KRW 5.95 tn) and Bio revenue fell ~10%. Gross margin nonetheless improved to 18.8% on mix and the faster-growing, higher-margin BTI-separate trading business.
FY2025: recovery begins. Revenue +8.0% to KRW 645.2 bn and operating profit +60.7% to KRW 27.0 bn, led by BTI-separate (+56.6%) riding Cosmax, Inc.'s record year, while NBT shrank (−9.5%) and booked a one-off US asset-disposal loss in Q3 2025 (Q3 consolidated net loss KRW 7.7 bn).
2026: inflection. Q1 2026 was the first quarter ever above KRW 200 bn revenue and KRW 10 bn operating profit; consolidated operating margin reached 8.0% (+3.8 pp YoY). H1 2026 operating profit doubled. Drivers: NBT's restructured footprint and China/Korea demand, Bio's recovery, and Cosmax, Inc.'s growth flowing through BTI-separate merchandise revenue, dividends and equity-method income.
Structural financial characteristics. (1) Thin consolidated margins (4–8%) relative to Cosmax, Inc. (8–9%); (2) a heavily current-weighted liability structure (86% of liabilities current at Q1 2026) implying short-term refinancing dependence; (3) liabilities at ~2.3x equity; (4) low interest coverage (~1.5x TTM). These are the principal financial vulnerabilities.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Structure
| Layer | Entity | BTI stake | Notes |
|---|---|---|---|
Apex | Cosmax BTI, Inc. | — | Controlled by Lee family (63.01% incl. related parties, June 2026) |
Associate | Cosmax, Inc. | 27.23% (27.51% incl. related) | ~34 consolidated subsidiaries (China, US, Indonesia, Thailand, Italy, Japan etc.) |
Subsidiary | Cosmax NBT | 43.53% | Korea, Australia, China, US entities |
Subsidiary | Cosmax Bio | 68.37% | Korea, China (Shanghai) |
Subsidiary | Cosmax Pharma | 79.64% | Korea |
Subsidiary (reported) | GrowX (그로우엑스) | — | — |
Segment revenue (KRW Bn)
| Segment revenue (KRW Bn) | Q1 2024 | Q2 2024 | Q1 2025 | Q1 2026 |
|---|---|---|---|---|
NBT (consolidated) | 71.0 | 80.9 | 72.2 | 93.3 |
BIO (consolidated) | 35.6 | 44.6 | 37.4 | 47.9 |
PHARMA | 10.8 | 8.3 | 8.5 | 8.6 |
BTI separate (holding) | 28.4 | 29.8 | 46.2 | 71.9 |
Consolidated revenue | 140.2 | 159.0 | 154.3 | 205.2 |
Segment net income (KRW Bn)
| Segment net income (KRW Bn) | Q1 2024 | Q2 2024 | Q1 2025 | Q1 2026 |
|---|---|---|---|---|
NBT | -6.4 | -0.5 | -2.3 | 9.1 |
BIO | -1.9 | -0.3 | -1.0 | 1.3 |
PHARMA | -2.3 | -2.6 | -1.5 | -1.7 |
BTI separate | 3.2 | 2.1 | 7.9 | 11.4 |
Annual revenue (KRW Bn)
| Annual revenue (KRW Bn) | FY2024 | FY2025 |
|---|---|---|
Cosmax NBT (consolidated) | 317.6 | 287.4 |
Cosmax Bio | 146.7 | 168.2 |
BTI separate | 113.5 | 177.7 |
Cosmax BTI consolidated | 597.6 | 645.2 |
Results by Segment
| Cosmax NBT (KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Operating income | 12.0 | 9.9 | 4.0 |
Net income | -5.8 | -5.4 | -15.1 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 576.0 | 617.4 | 628.6 | 597.6 | 645.2 |
Gross profit (KRW Bn) | 92.2 | 88.3 | 110.0 | 112.3 | 135.5 |
Operating income (KRW Bn) | 11.9 | 3.4 | 20.2 | 16.8 | 27.0 |
Net income (KRW Bn) | 4.3 | -20.2 | 2.5 | 8.0 | 20.9 |
Gross margin (%) | 16.0 | 14.3 | 17.5 | 18.8 | 21.0 |
Operating margin (%) | 2.1 | 0.6 | 3.2 | 2.8 | 4.2 |
Net margin (%) | 0.7 | -3.3 | 0.4 | 1.3 | 3.2 |
Revenue growth YoY (%) | 0.0 | 7.2 | 1.8 | -4.9 | 8.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement
| Metric | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 140.2 | 159.0 | 151.9 | 146.5 | 154.3 | 163.7 | 153.5 | 173.7 | 205.2 | 238.9 |
Operating income (KRW Bn) | 2.2 | 6.9 | 3.3 | 4.4 | 6.5 | 9.9 | 3.2 | 7.4 | 16.4 | 16.2 |
Income Statement and Margin Analysis (%) (Half-Yearly)
| Metric | H1 2025 | H1 2026 |
|---|---|---|
Revenue (KRW Bn) | 318.0 | 444.1 |
Operating income (KRW Bn) | 16.4 | 32.6 |
Net income (KRW Bn) | 5.8 | 65.7 |
Operating margin (%) | 5.2 | 7.3 |
Financial Analysis
| Line item | Q1 2025 | Q1 2026 |
|---|---|---|
Revenue | 154.3 | 205.2 |
Cost of sales | 122.6 | 158.9 |
Gross profit | 31.7 | 46.3 |
SG&A | 25.2 | 29.9 |
Operating income | 6.5 | 16.4 |
Non-operating income/expense | -5.8 | -2.7 |
Equity-method income | 0.8 | 11.0 |
Pre-tax income | 1.5 | 24.7 |
Net income | -1.4 | 19.2 |
Net income attributable to owners | 0.7 | 14.1 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2024 | FY2025 | Q1 2026 |
|---|---|---|---|
Total assets (KRW Bn) | 953.9 | 1,006.3 | 1,050.1 |
Total liabilities (KRW Bn) | 672.7 | 710.6 | 733.9 |
Total equity (KRW Bn) | 281.2 | 295.7 | 316.2 |
Liabilities-to-equity (%) | 239.2 | 240.3 | 232.1 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet
| Balance sheet detail (KRW Bn) | FY2025 | Q1 2026 |
|---|---|---|
Current assets | 349.9 | 380.0 |
Non-current assets | 656.4 | 670.1 |
Current liabilities | 628.1 | 630.8 |
Non-current liabilities | 82.5 | 103.1 |
Share capital | 4.8 | 4.8 |
Capital surplus | 235.0 | 235.4 |
Other capital | -97.8 | -89.3 |
Retained earnings | 133.5 | 140.6 |
Non-controlling interests | 20.2 | 24.7 |
Per-share (KRW)
| Per-share (KRW) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Dividend per share (KRW) | 350 | 450 | 780 |
Financial Analysis — ROE
| Ratio | Value | Basis / source |
|---|---|---|
ROE | 11.1% | FY2025, FnGuide |
ROE (TTM) | 19.7% | Butler, Oct 2026 |
ROA | ≈2.1% | FY2025 net income / average assets (derived) |
ROIC | 2.6% | MarketInOut TTM (Aug 2026) |
Current ratio | 0.56x (FY2025); 0.60x (Q1 2026) | Derived |
Liabilities / equity | 2.40x (FY2025); 2.32x (Q1 2026) | Derived |
Debt / equity | 1.75x | MarketInOut TTM (definition: financial debt) |
Interest coverage | 1.51x | MarketInOut TTM |
EV / EBITDA | 6.5x (MarketInOut); 10.2x (FnGuide) | Vendor definitions differ |
EBITDA (TTM) | KRW 99.5 bn | MarketInOut, Aug 2026 — unaudited vendor calculation |
NBT revenue by region (KRW Bn)
| NBT revenue by region (KRW Bn) | FY2024 | FY2025 |
|---|---|---|
Overseas (KRW Bn) | 221.6 | 181.7 |
Domestic (KRW Bn) | 96.0 | 105.7 |
Group Entities
| Entity | Q1 2026 revenue (KRW Bn) | YoY growth (%) |
|---|---|---|
NBT Korea | 72.6 | 40.6 |
NBT Australia | 19.5 | 82.1 |
NBT USA | 3.5 | -37.5 |
Bio Korea | 39.7 | 26.7 |
Bio China | 4.8 | 39.9 |
Revenue by Region
| Cosmax, Inc. region (KRW Bn) | FY2024 | FY2025 |
|---|---|---|
Korea (separate) | 1,357.7 | 1,526.4 |
China (consolidated East) | 574.3 | 632.7 |
Cosmax BTI share price (KRW)
| Cosmax BTI share price (KRW) | 31 Mar 2020 | 28 Oct 2025 | 5 Nov 2025 | 27 Mar 2026 | 6 Oct 2026 | 14 Oct 2026 |
|---|---|---|---|---|---|---|
Closing price (KRW) | 10,750 | 14,840 | 13,690 | 16,190 | 23,850 | 22,850 |
Performance Details
| Performance | Value |
|---|---|
~1-year (28 Oct 2025 → 14 Oct 2026) | ≈+54% (derived) |
Since 31 Mar 2020 | ≈+113% (derived) |
52-week range | KRW 11,810 – 29,150 |
Beta (1-year) | 0.41–0.58 (FnGuide, differing dates) |
Valuation Multiples
| Multiple | Cosmax BTI | Cosmax, Inc. | Source |
|---|---|---|---|
P/E (TTM) | ≈3.5x | ≈19.8x | Judal |
P/B | ≈0.69x | ≈5.3x | Judal |
EV/EBITDA | 6.5x–10.2x (vendor-dependent) | 10.3x (2026E, Hanwha) | MarketInOut, FnGuide, Hanwha |
EV/Sales | ≈0.93x | — | MarketInOut |
Dividend yield | ≈3.4% (KRW 780 / KRW 22,850) | ≈1.1% (KRW 3,300 / KRW 306,500) | Derived |
Holding Details
| Holding | Shares held (approx.) | Price (KRW) | Value (KRW Bn) |
|---|---|---|---|
Cosmax, Inc. (27.23%) | 3.09 m | 306,500 (9 Oct) | ≈947 |
Cosmax NBT (43.53%) | 8.98 m | 5,080 (15 Oct) | ≈46 |
Listed holdings total | — | — | ≈993 |
Cosmax BTI market cap | 9.60 m | 22,850 (14 Oct) | ≈219 |
Analyst Conclusions
Guidance and expectations
BTI: no numeric guidance; qualitative direction is continued HFF export growth, portfolio diversification and pharma product launches. H1 2026 run-rate (revenue KRW 444.1 bn, OP KRW 32.6 bn) implies FY2026 revenue plausibly above KRW 850 bn and OP above KRW 55 bn if H2 merely matches H1 — an illustrative extrapolation, not guidance.
NBT: DS Investment projects 2026 revenue KRW 374.6 bn (+30%).
Cosmax, Inc.: H1 2026 revenue KRW 1,476.9 bn (+22%) and OP KRW 126.8 bn (+13%); management expects US turnaround and skincare momentum to continue in H2.
Bull case
-
Discount closure: with listed stakes worth ~4.5x market cap, modest discount narrowing (e.g., via higher payouts, value-up pressure, or simplification) offers large upside.
-
HFF operating leverage: NBT's restructured cost base produced a 11% OPM in Q1 2026; sustained growth of 30% could make HFF a genuine second profit engine.
-
Associate compounding: Cosmax, Inc.'s US profitability, Europe entry and L'Oréal partnership extend its growth runway, raising equity-method income and dividends to BTI.
Bear case
-
Leverage and liquidity: liabilities 2.3x equity, current ratio 0.6x and ~1.5x interest coverage leave little margin for error if HFF demand falters.
-
Earnings quality: 2026 profits are flattered by one-offs (KRW 25.7 bn tax refund) and equity-method income BTI cannot freely access; underlying HFF growth has historically proven cyclical.
-
Governance overhang: controlling-family stake of 63%, succession via personal companies and an abrupt professional-CEO exit may keep minority-shareholder discounts structurally wide.
Catalysts and monitorables (next 12 months)
-
Q3 2026 results (expected mid-November 2026): NBT growth sustainability ex-tax refund; BTI-separate revenue.
-
FY2026 dividend decision (Q1 2027): payout and high-dividend status renewal.
-
Second NBT US plant sale and deleveraging.
-
Cause and resolution of NBT's ~55% share-price decline from its 52-week high.
-
Any group restructuring, merger or stake simplification following the May 2026 control transfer.
-
Execution of Keminova integration and first L'Oréal joint projects.
-
Korean holding-company/value-up regulatory developments.
Concluding analyst verdict
Cosmax BTI presents one of the clearest examples on the Korean market of a holding company whose share price detaches from the value of what it owns. At roughly KRW 219 bn, the market values BTI at about a fifth of the market value of its Cosmax, Inc. and Cosmax NBT stakes alone, while ignoring unlisted Cosmax Bio and Pharma. The discount is not irrational, but it is extreme. It reflects real issues: a consolidated balance sheet carrying liabilities more than twice equity with most of them current, interest coverage near 1.5x, a decade of disappointing HFF returns, missed targets at Cosmax Bio, and a governance model in which the founding family controls about 63% and has used personal companies to engineer succession.
What has changed in 2026 is the operating evidence. For the first time the consolidated business is compounding at scale — Q1 revenue +33%, H1 operating profit roughly doubled — and the improvement is rooted in structural action (exiting US HFF manufacturing) and exogenous tailwinds (K-beauty and K-wellness exports, China recovery) rather than accounting alone, although H1 net income is inflated by a one-off tax refund. Meanwhile the associate, Cosmax, Inc., has delivered record quarters, a first US profit, a European foothold and a high-profile L'Oréal partnership.
The investment debate therefore reduces to governance and capital allocation rather than operations. If the newly consolidated family leadership under Lee Byung-joo (holding) and Lee Byung-man (cosmetics) uses the earnings upswing to deleverage, raise payouts further and simplify the structure, the discount could narrow materially. If the holding structure continues to serve primarily as a control and succession vehicle, the stock may remain a perennially "cheap" proxy.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / background | Age / born |
|---|---|---|---|
Lee Kyung-soo | Founder; Chairman, Cosmax BTI | Founded group 1992; transferred all personal BTI shares to sons by 2023 | Born 1946 |
Suh Sung-suk | Co-founder; Chairwoman (Group HR) | Largest shareholder until May 2026; now 13.83% | Born 1952 |
Lee Byung-joo | Vice Chairman & sole CEO, Cosmax BTI (since 10 Sep 2026) | Joined group 20+ years ago; roles in talent development, management support; headed Cosmax NBT USA and Cosmax USA; Cosmax, Inc. CEO 2023–Mar 2025 | Born 1979 |
Lee Byung-man | Vice Chairman & CEO, Cosmax, Inc.; largest BTI shareholder | Joined Cosmax 2005; led overseas marketing at BTI from 2016; Cosmax CEO 2020–2023 and again from Mar 2025; BTI CEO 2023–2025; MBA, Shanghai Jiao Tong University | Born 1978 |
Huh Min-ho | Former Senior Vice Chairman & co-CEO, Cosmax BTI | Ex-CEO of CJ Olive Young and CJ ENM Commerce; joined Mar 2025; resigned 10 Sep 2026 citing personal reasons | Age 62 (2026) |
Choi Kyung | Vice Chairman & co-CEO, Cosmax, Inc. | Signed L'Oréal MOU (Sep 2026) | — |
Kim Nam-joong | CEO, Cosmax NBT | Received ministerial commendation (Dec 2025) | — |
Kim Yong-beom | Head of Group Planning & Management, Cosmax BTI | Inside director of SSY | — |
Shin Yoon-seo | Head of Group Finance, Cosmax BTI | Inside director of BJH | — |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change | Context |
|---|---|---|
Mar 2023 | Lee Byung-man and Lee Byung-joo appointed BTI co-CEOs | Replaced professional managers |
27 Mar 2025 | Lee Byung-man moves to Cosmax, Inc. CEO; Lee Byung-joo to BTI; Huh Min-ho joins as BTI co-CEO | Brother role swap; professional retail executive added |
Late 2025 | Brothers promoted to Vice Chairman; Huh to Senior Vice Chairman | Generational transition |
10 Sep 2026 | Huh resigns; Lee Byung-joo sole CEO | Company says no business issue involved |
Major Shareholders
| Shareholder | Stake | Date / source |
|---|---|---|
Lee Byung-man (largest shareholder) | 19.95% direct | June 2026 (Asia Today) |
Suh Sung-suk | 13.83% | June 2026 |
Lee Byung-joo | 10.52% | June 2026 |
Cos M&M (family-owned company) | 9.43% | 2025 |
SSY Co. (100% Lee Byung-man) | ≈4.39% (421,670 shares) | May 2026 |
BJH Co. (100% Lee Byung-joo) | ≈4.39% (421,670 shares) | May 2026 |
Largest shareholder + related parties | 63.01% | June 2026 |
Unnamed 5%+ holder | 5.59% (537,179 shares) | — |
Treasury shares | 0.51% | — |
Minority shareholders (4,019 holders) | 32.7% | FY2025 annual report |
Competitive Landscape
Peer Comparison FY2025
| Company | Revenue | Revenue growth YoY | Operating margin | R&D intensity |
|---|---|---|---|---|
Cosmax BTI (consolidated) | KRW 645.2 bn | +8.0% | 4.2% | — |
Cosmax, Inc. (associate) | KRW 2,398.8 bn | +10.7% | 8.2% | 5.54% (2026) |
Kolmar Korea | KRW 2,722.4 bn | — | 8.8% | — |
Novarex | KRW 404.3 bn | +36% | 10.7% | — |
Intercos | ≈€1.05 bn | ≈0% to −1.7% (sources differ) | Adj. EBITDA margin 14.9% | — |
“—” = not publicly disclosed.



